Swiss HPB and Transplant Center, Department of Surgery, University Hospital Zurich, Switzerland.
Ann Surg. 2012 Nov;256(5):861-8; discussion 868-9. doi: 10.1097/SLA.0b013e318272dea2.
To integrate the amount of hepatic steatosis in modern liver allocation models.
The aim of this study was to combine the 2 largest liver transplant databases (United States and Europe) in 1 comprehensive model to predict outcome after liver transplantation, with a novel focus on the impact of the presence of steatosis in the graft.
We adjusted the balance of risk (BAR) score for its application to the European Liver Transplant Registry (ELTR) database containing 11,942 patients. All liver transplants from ELTR and United Network for Organ Sharing with recorded liver biopsies were then combined in one survival analysis in relation to the presence of graft micro- (n = 9,677) and macrosteatosis (n = 11,516).
Microsteatosis, regardless of the amount, was associated with a similar relationship between mortality and BAR score as nonsteatotic livers. Low-grade macrosteatotic liver grafts (≤30% macrosteatosis) resulted in 5-year graft-survival rates of 60% or more up to BAR 18, comparable to nonsteatotic grafts. However, use of moderate or severely steatotic liver grafts (>30% macrosteatosis) resulted in acceptable outcome only if the cumulative risk at transplant was low, that is, BAR score of 9 or less.
Microsteatotic or 30% or less macrosteatotic liver grafts can be used safely up to BAR score of 18 or less, but liver grafts with more than 30% macrosteatotis should be used with risk adjustment, that is, up to BAR score of 9 or less.
将肝脂肪变性量纳入现代肝脏分配模型中。
本研究旨在将 2 个最大的肝移植数据库(美国和欧洲)合并为 1 个综合模型,以预测肝移植后的结局,其重点是新出现的供体脂肪变性对结局的影响。
我们调整了平衡风险(BAR)评分,以将其应用于包含 11942 例患者的欧洲肝移植登记处(ELTR)数据库。然后,将来自 ELTR 和美国器官共享联合网络的所有记录有肝活检的肝移植病例合并到 1 个生存分析中,与供体微(n=9677)和宏观脂肪变性(n=11516)的存在相关。
无论脂肪变性程度如何,微脂肪变性与非脂肪变性肝脏的死亡率与 BAR 评分之间均存在相似的关系。低级别脂肪变性的肝移植物(≤30%脂肪变性)可使 5 年移植物存活率达到 60%或更高,直至 BAR 18,与非脂肪变性移植物相当。然而,只有在移植时累积风险较低(即 BAR 评分 9 或更低)时,使用中度或重度脂肪变性的肝移植物(>30%脂肪变性)才能获得可接受的结果。
微脂肪变性或 30%或更少的脂肪变性肝移植物可安全使用至 BAR 评分 18 或更低,但脂肪变性超过 30%的肝移植物应进行风险调整,即使用至 BAR 评分 9 或更低。